Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry

Autoimmunity Reviews

Volumn 17, Issue 7, 2018, Pages 653-659

  Jardel, Sabine ^a   Puéchal, Xavier ^b   Le Quellec, Alain ^c   Pagnoux, Christian ^b,q   Hamidou, Mohamed ^d   Maurier, François ^e   Aumaitre, Olivier ^f   Aouba, Achille ^g   Quemeneur, Thomas ^h   Subra, Jean François ⁱ   Cottin, Vincent ^a   Sibilia, Jean ^j   Godmer, Pascal ^k   Cacoub, Patrice ^l,m,n   Fauchais, Anne Laure ^o   Hachulla, Eric ^p   Maucort Boulch, Delphine ^a   Guillevin, Loïc ^b   Lega, Jean Christophe ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Institut Cochin   (France)

^c HÔPITAL SAINT ELOI   (France)

^d HÔTEL DIEU   (France)

^e Site Belle Isle ^*  (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER DE VALENCIENNES   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k Centre Hospitalier Bretagne Atlantique   (France)

^l SORBONNE UNIVERSITÉ   (France)

^m Sorbonne Université   (France)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o DUPUYTREN UNIVERSITY HOSPITAL   (France)

^p UNIV LILLE   (France)

^q MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALL CAUSE MORTALITY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; EOSINOPHILIC GRANULOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MORTALITY; NECROTIZING ARTERITIS; NECROTIZING VASCULITIDES; OVERALL SURVIVAL; POLYARTERITIS NODOSA; RETROSPECTIVE STUDY; REVIEW; WEGENER GRANULOMATOSIS; FRANCE; INCIDENCE; PATHOPHYSIOLOGY; PROGNOSIS; REGISTER; SURVIVAL RATE;

FRANCE; HUMANS; INCIDENCE; POLYARTERITIS NODOSA; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85046811935     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2018.01.022     Document Type: Review

References (41)

1. Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C., Ferrario, F. et al., Revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 65 (2012), 1–11.
2. De Virgilio, A., Greco, A., Magliulo, G., Gallo, A., Ruoppolo, G., Conte, M. et al., Polyarteritis nodosa: a contemporary overview. Autoimmun Rev 15 (2016), 564–570.
3. Frohnert, P.P., Sheps, S.G., Long-term follow-up study of periarteritis nodosa. Am J Med 43 (1967), 8–14.
4. Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J.W.C., Dadoniené J. et al., A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003), 36–44.
5. Stone, J.H., Merkel, P.A., Spiera, R., Seo, P., Langford, C.A., Hoffman, G.S. et al., Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 (2010), 221–232.
6. Guillevin, L., Lhote, F., Gayraud, M., Cohen, P., Jarrousse, B., Lortholary, O. et al., Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 (1996), 17–28.
7. Guillevin, L., Pagnoux, C., Seror, R., Mahr, A., Mouthon, L., Le Toumelin, P. et al., The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 (2011), 19–27.
8. Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arène, J.-P., Lauque, D. et al., Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58 (2008), 586–594.
9. Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arène, J.-P., Puéchal, X. et al., Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62 (2010), 1186–1197.
10. Samson, M., Puéchal, X., Devilliers, H., Ribi, C., Cohen, P., Bienvenu, B. et al., Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev 13 (2014), 197–205.
11. Samson, M., Puéchal, X., Devilliers, H., Ribi, C., Cohen, P., Bienvenu, B. et al., Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev 13 (2014), 945–953.
12. Pagnoux, C., Mahr, A., Hamidou, M.A., Boffa, J.-J., Ruivard, M., Ducroix, J.-P. et al., Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359 (2008), 2790–2803.
13. Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P. et al., Rituximab versus azathioprine for maintenance in ANCA-associated Vasculitis. N Engl J Med 371 (2014), 1771–1780.
14. Pagnoux, C., Quémeneur, T., Ninet, J., Diot, E., Kyndt, X., de Wazières, B. et al., Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67 (2015), 1117–1127.
15. Stratta, P., Marcuccio, C., Campo, A., Sandri, L., Messuerott, A., Colla, L. et al., Improvement in relative survival of patients with vasculitis: study of 101 cases compared to the general population. Int J Immunopathol Pharmacol 21 (2008), 631–642.
16. Holle, J.U., Gross, W.L., Latza, U., Nölle, B., Ambrosch, P., Heller, M. et al., Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63 (2011), 257–266.
17. Solans-Laqué R., Fraile, G., Rodriguez-Carballeira, M., Caminal, L., Castillo, M.J., Martínez-Valle, F. et al., Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides. Medicine (Baltimore) 96 (2017), e6083–10.
18. Eriksson, P., Jacobsson, L., Lindell, Å., Nilsson, J.Å., Skogh, T., Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 265 (2009), 496–506.
19. Karras, A., Pagnoux, C., Haubitz, M., Groot, K., Puéchal, X., JWC, Tervaert et al., Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76 (2017), 1662–1668.
20. Guillevin, L., Cohen, P., Mahr, A., Arène, J.-P., Mouthon, L., Puéchal, X. et al., Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49 (2003), 93–100.
21. Cohen, P., Pagnoux, C., Mahr, A., Arène, J.-P., Mouthon, L., Le Guern, V. et al., Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57 (2007), 686–693.
22. Puéchal, X., Pagnoux, C., Baron, G., Quémeneur, T., Néel, A., Agard, C. et al., Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with Polyangiitis, microscopic Polyangiitis or Polyarteritis Nodosa without poor prognosis factors a randomized-controlled trial. Arthritis Rheumatol 69 (2017), 2175–2186.
23. Hiemstra, T.F., Walsh, M., Mahr, A., Savage, C.O., de Groot, K., Harper, L. et al., Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304 (2010), 2381–2388.
24. de Menthon, M., Cohen, P., Pagnoux, C., Buchler, M., Sibilia, J., Détrée, F. et al., Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29 (2011), S63–71.
25. Lightfoot, R.W., Michel, B.A., Bloch, D.A., Hunder, G.G., Zvaifler, N.J., McShane, D.J. et al., The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33 (1990), 1088–1093.
26. Leavitt, R.Y., Fauci, A.S., Bloch, D.A., Michel, B.A., Hunder, G.G., Arend, W.P. et al., The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33 (1990), 1101–1107.
27. Masi, A.T., Hunder, G.G., Lie, J.T., Michel, B.A., Bloch, D.A., Arend, W.P. et al., The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33 (1990), 1094–1100.
28. Novikov, P.I., Moiseev, S.V., Kuznetsova, E.I., Semenkova, E.N., Mukhin, N.A., Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatol Int 35 (2015), 891–898.
29. Wallace, Z.S., Lu, N., Unizony, S., Stone, J.H., Choi, H.K., Improved survival in granulomatosis with polyangiitis: a general population-based study. Semin Arthritis Rheum 45 (2016), 483–489.
30. Tan, J.A., Dehghan, N., Chen, W., Xie, H., Esdaile, J.M., Avina-Zubieta, J.A., Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis 76:9 (2017), 1566–1574.
31. Terrier, B., Pagnoux, C., Perrodeau, É., Karras, A., Khouatra, C., Aumaître, O., Rituximab versus azathioprine to maintain remission of ANCA-associated vasculitides (MAINRITSAN): follow-up at 60 months (abstract). Arthritis Rheum, 68(Suppl 10), 2016, 2971.
32. Bourgarit, A., Toumelin, P.L., Pagnoux, C., Cohen, P., Mahr, A., Guern, V.L. et al., Deaths occurring during the first year after treatment onset for Polyarteritis Nodosa, microscopic Polyangiitis, and Churg-Strauss syndrome. Medicine (Baltimore) 84 (2005), 323–330.
33. Flossmann, O., Berden, A., de Groot, K., Hagen, C., Harper, L., Heijl, C. et al., Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70 (2011), 488–494.
34. Heijl, C., Harper, L., Flossmann, O., Stücker, I., Scott, D.G.I., Watts, R.A. et al., Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70 (2011), 1415–1421.
35. Mahr, A., Heijl, C., Le Guenno, G., Faurschou, M., ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 27 (2013), 45–56.
36. van Daalen, E.E., Rizzo, R., Kronbichler, A., Wolterbeek, R., Bruijn, J.A., Jayne, D.R. et al., Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 76 (2017), 1064–1069.
37. Suppiah, R., Judge, A., Batra, R., Flossmann, O., Harper, L., Höglund, P. et al., A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 63 (2011), 588–596.
38. Weiner, M., Goh, S.M., Mohammad, A.J., Hruskova, Z., Tanna, A., Bruchfeld, A. et al., Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol 10 (2015), 1128–1135.
39. Puéchal, X., Pagnoux, C., Perrodeau, É., Hamidou, M., Boffa, J.-J., Kyndt, X. et al., Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Arthritis Rheumatol 68 (2016), 690–701.
40. Harper, L., ANCA-associated renal vasculitis at the end of the twentieth century–a disease of older patients. Rheumatology (Oxford) 44 (2005), 495–501.
41. Pagnoux, C., Carette, S., Khalidi, N.A., Walsh, M., Hiemstra, T.F., Cuthbertson, D. et al., Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33 (2015), 77–83.